Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study.

Kerget, Bugra; Çil, Gizem; Araz, Ömer; Alper, Fatih; Akgün, Metin

Kerget, Bugra; Çil, Gizem; Araz, Ömer; Alper, Fatih; Akgün, Metin.

Afiliación

Kerget B; Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240 Yakutiye, Erzurum, Turkey. Electronic address: bjkerget1903@gmail.com.
Çil G; Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240 Yakutiye, Erzurum, Turkey.
Araz Ö; Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240 Yakutiye, Erzurum, Turkey.
Alper F; Department of Radiology, Ataturk University School of Medicine, 25240 Yakutiye, Erzurum, Turkey.
Akgün M; Department of Pulmonary Diseases, Agri Ibrahim Çeçen University School of Medicine, 04100 Agri, Turkey.

Med Clin (Barc) ; 160(12): 525-530, 2023 06 23.

Article en En, Es | MEDLINE | ID: mdl-37055254

Asunto(s)

Antifibróticos; Síndrome Post Agudo de COVID-19; Fibrosis Pulmonar; Piridonas; Adulto; Anciano; Femenino; Humanos; Masculino; Persona de Mediana Edad; Antifibróticos/efectos adversos; Antifibróticos/uso terapéutico; Estudios de Seguimiento; Síndrome Post Agudo de COVID-19/complicaciones; Estudios Prospectivos; Fibrosis Pulmonar/tratamiento farmacológico; Fibrosis Pulmonar/epidemiología; Piridonas/efectos adversos; Piridonas/uso terapéutico; Resultado del Tratamiento

Palabras clave

COVID-19; Nintedanib; Pirfenidona; Pirfenidone

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fibrosis Pulmonar / Piridonas / Antifibróticos / Síndrome Post Agudo de COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En / Es Revista: Med Clin (Barc) Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google